Joint regeneration Queen Creek: help for ongoing soreness

What to try while the joint settles

You might first shorten the activity that clearly brings on the ache, then use the joint only as far as feels easy because complete rest can leave it stiffer. If walking hurts, a shorter outing may be kinder than stopping all movement. Your joint still needs gentle use.

For soreness in a knee or hip, standing slowly from a sturdy chair helps build strength, while a shoulder may benefit when you press your palm gently against a wall without moving the arm. The exercise shouldn’t make soreness suddenly much worse. Give it several weeks unless the joint becomes worse, and ask a physical therapist for help.

A brace or walking cane can help when a leg feels weak or gives way, while medicine rubbed on the skin is called topical medicine. Pills work through the whole body. Your doctor can check which kind is safe with your health and other medicines. Please don’t use another person’s medicine.

Notice when swelling, stiffness, or sleep trouble appears during the day. You don’t need a long diary; a few notes about the troublesome activity will do. Bring them if you arrange an appointment, since they’ll help keep the talk useful.

When to have the joint checked

When should you have the joint examined? It’s time if soreness often returns, makes ordinary tasks harder, or isn’t easing with home care. Your doctor may watch you move, press around the joint, and look at an earlier X-ray to separate long wear from a newer injury.

At a QC Kinetix consultation, trained medical providers can look at how the joint moves and explain non-surgical care. One choice may be PRP; those letters mean platelet-rich plasma, prepared after the office spins blood taken from you. That prepared part is then used for the sore joint. You can ask about expected relief, limits, full cost, and later visits before deciding.

Sources

1. Roughly 14 million people in the United States have symptomatic knee osteoarthritis, and more than half of them are under 65 - with nearly 2 million under 45. The market for a cash-pay procedure sold as an alternative to joint replacement is largely working-age people who are being told they are too young for surgery.

   Deshpande BR, et al. — Number of Persons With Symptomatic Knee Osteoarthritis in the US: Impact of Race and Ethnicity, Age, Sex, and Obesity.. Arthritis care & research, 2016. DOI: 10.1002/acr.22897.

2. The lifetime risk of developing symptomatic knee osteoarthritis is approximately 45%, rising with obesity and with a history of significant knee injury. Almost half of all adults will eventually face the decisions this topic describes.

   Murphy L, et al. — Lifetime risk of symptomatic knee osteoarthritis.. Arthritis and rheumatism, 2008. DOI: 10.1002/art.24021.

3. The AAOS third-edition clinical practice guideline for non-arthroplasty management of knee osteoarthritis is the orthopedic profession's own GRADE-style appraisal of the same options a regenerative clinic sells; it is the benchmark against which any 'regenerative' claim on this topic should be read, and it rates the strongest support for exercise, weight loss and self-management rather than for injectables.

   Brophy RH, et al. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. The Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.

4. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

5. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.